ImmunoGen Inc (NASDAQ:IMGN)
| 5.25 Delayed Data As of 3:59pm ET |  -0.06 / -1.13%Today’s Change | 3.10 Today|||52-Week Range 7.77 | -29.25% Year-to-Date |
Latest IMGN News | Press Releases
| ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates Aug 01 / Zacks.com - Paid Partner Content | ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates Jul 29 / Zacks.com - Paid Partner Content |
| ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript Jul 30 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 5.31 |
| Today’s open | 5.29 |
| Day’s range | 5.20 - 5.51 |
| Volume | 258,567 |
| Average volume (3 months) | 3,504,830 |
| Market cap | $1.2B |
Data as of 3:59pm ET, 08/11/2022
Growth & Valuation
| Earnings growth (last year) | -168.28% |
| Earnings growth (this year) | -28.41% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -47.20% |
| P/E ratio | NM |
| Price/Sales | 21.90 |
| Price/Book | 3.69 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CDMOAvid Bioservices Inc | -0.26 | -1.35% |
| DCPHDeciphera Pharmaceut... | -1.44 | -8.37% |
| AUPHAurinia Pharmaceutic... | -0.34 | -4.00% |
| MRUSMerus NV | -1.33 | -5.05% |
Data as of 4:00pm ET, 08/11/2022
Financials
| Next reporting date | October 28, 2022 |
| EPS forecast (this quarter) | -$0.26 |
| Annual revenue (last year) | $69.9M |
| Annual profit (last year) | -$139.3M |
| Net profit margin | -199.41% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Waltham, Massachusetts |
Forecasts
